Melatonin by Pévet, Paul
Melatonin (MEL) is a hormone synthesized and secreted
by the pineal gland deep within the brain in response to
photoperiodic cues relayed from the retina via an
endogenous circadian oscillator within the suprachias-
matic nucleus in the hypothalamus. The circadian rhythm
of melatonin production and release, characterized by
nocturnal activity and daytime quiescence, is an impor-
tant temporal signal to the body structures that can read
it. Melatonin acts through high-affinity receptors located
centrally and in numerous peripheral organs. Different
receptor subtypes have been cloned and characterized:
MT1 and MT2 (transmembrane G-protein–coupled recep-
tors), and MT3. However, their physiological role remains
unelucidated, although livestock management applica-
tions already include the control of seasonal breeding and
milk production. As for potential therapeutic applications,
exogenous melatonin or a melatonin agonist and selec-
tive 5-hydroxytryptamine receptor (5-HT2c) antagonist,
eg, S 20098, can be used to manipulate circadian process-
es such as the sleep–wake cycle, which are frequently dis-
rupted in many conditions, most notably seasonal affec-
tive disorder.
aily and seasonal rhythms in endocrine,physio-
logical,and behavioral processes are a fundamental fea-
ture of all living organisms reflecting a need to ensure
that biological functions occur at a given time of the day
or year.The most obvious example is the fact that many
animals are active only during the hours of daylight
(diurnal species; human belong to this group) or the
hours of darkness (nocturnal species), and are inactive
during the other part of the day (sleep–wake cycle).
Other rhythms, like hibernation, fur color changes, and
migration,can also be given as examples.
In human, disruptions of rhythmicity are characteristic
of,and may underlie,a variety of disorders.For example,
sleep and circadian rhythms are often disrupted in neu-
rological disorders, and increasing evidence indicates
that alterations in the sleep–wake cycle accompany such
neurological disorders. Moreover, delayed resynchro-
nization to local time (jet lag) or with rotation of shift
work is associated with general malaise (especially
insomnia), a reduction in productivity at work, and an
increase in numbers of accidents.
The challenge for scientists is to understand the func-
tional mechanisms involved and to develop strategies to
control or treat such disorders (eg, to accelerate resyn-
chronization to new work schedules or to treat endoge-
nous depression or sleep disorders).
The mechanism used for the daily or seasonal organiza-
tion of functions is far from being well understood.
Today, however, we know that this mechanism is built
around three key components: (i) photoreceptors regis-
tering and transmitting environmental light cues; (ii)
“clocks” that generate rhythms with a period of about
24 h and are capable of being entrained to exactly 24 h,
especially by the light–dark (LD) cycle; and (iii)
endocrine and neuroendocrine effectors receiving signals
from the clock and translating them into a hormonal or
neurohormonal response. Over the past few years, the
huge surge in molecular biology has led to the identifi-
cation of several clock genes (Per1, Per2, Per3, Clock,
BMAL1, Cry1, Cry2, and Caseine kinase ε).These find-
ings led to a molecular model of circadian oscillations
based on two interlocking transcriptional/translational
feedback loops.
1,2 The timing information built into the
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Dclock,via nervous and endocrine pathways,is forwarded
to specialized structures.Among these structures is the
pineal gland, which secretes the hormone melatonin
(MEL), whose role and mechanisms of action will be
analyzed in this review.
Synthesis and production of melatonin
In 1917,McCord and Allen reported that bovine pineal
extracts were potent frog skin lightening factors.
3 In
1958,Lerner et al isolated the agent responsible for the
observed aggregation of melanophores, N-acetyl-5-
methoxytryptamine,and termed it melatonin.
4
The synthesis of MEL within the pineal gland is mainly
regulated by the daily and seasonal changes in the envi-
ronmental LD cycle.The synthesis of MEL is markedly
increased at night in all species studied to date, inde-
pendent of whether the animal is diurnally or noctur-
nally active, and the duration of the nocturnal peak is
positively related to the duration of the night.
5,6 In non-
mammalian vertebrates, the rhythmic synthesis and
secretion of MEL is the direct output of the clock locat-
ed within the pineal. In mammals, however, the pineal
does not retain clock and photoreceptive properties.The
synthesis of MEL is driven through multisynaptic neur-
al pathways
7,8 by the circadian clock located in the
suprachiasmatic nuclei (SCN) of the hypothalamus,and
is therefore also an output of the circadian clock.
MEL is synthesized from the amino acid tryptophan,
which is first converted into 5-hydroxytryptophan by
tryptophan hydroxylase, before being decarboxylated
into serotonin (5-hydroxytryptamine, 5-HT). From 
5-HT,two major enzymatic steps are involved.The first is
N-acetylation by the arylalkylamine-N-acetyltransferase
(AA-NAT) to yield N-acetylserotonin.The regulation of
AA-NAT, with its sharp increase in activity at night, has
received considerable attention as a major regulatory
step in rhythmic MEL synthesis.
9,10The second step is the
transfer of a methyl group from 5-adenosylmethionine to
the 5-hydroxy group of N-acetylserotonin catalyzed by
the hydroxyindole O-methyltransferase (HIOMT), to
yield MEL.
11 The rapid 6-hydroxylation of MEL in the
liver means that it has a short half-life in the circulation
and, therefore, the circulating MEL concentrations pre-
cisely reflect its pineal synthesis.
MEL is produced primarily by the pineal gland. How-
ever, numerous other MEL sources have been identi-
fied. The retina is an important source in nonmam-
malian vertebrates: not only is MEL rhythmically
synthesized in this structure, but its release from here
also contributes to the nocturnal pattern of circulating
MEL.In mammals,MEL synthesis within the retina was
demonstrated a long time ago.
12 However,it is only since
the demonstration of a true circadian release of MEL
from the hamster retina in vitro (suggesting the pres-
ence of a retinal clock) that the importance of this struc-
ture as an extrapineal source of MEL has been recog-
nized.
13 In contrast to nonmammalian vertebrates,
mammalian retinal MEL does not contribute to circu-
lating MEL.The Harderian and lachrymal glands, gas-
trointestinal tract, red blood cells, platelets, and
mononuclear cells have also been identified as sites of
MEL synthesis.MEL does not seem to be released into
the general circulation from these tissues, at least not
under normal physiological conditions.
14 Moreover, in
these tissues the synthesis of MEL is not rhythmic.
The presence of MEL is not restricted to vertebrates.
MEL has been found in the head, eyes, optic lobe, and
brain of various invertebrates in many taxa.
15 MEL has
also been shown to be formed in fungi,plants,multicel-
lular algae,and unicellular organisms.
16,17
Sites of action of melatonin and 
signal transduction pathways
Before we start the description of present knowledge on
the mechanisms involved, it should be mentioned that
MEL has been reported to be a potent free-radical scav-
enger at high doses.
18This pharmacological effect can be
explained through direct scavenging of free radicals or
through interactions with enzymes that improve total
antioxidative defense capacity.This effect should not be
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Selected abbreviations and acronyms
4P-ADOT 4-phenylacetamidotetraline
cAMP cyclic adenosine monophosphate
5-HT 5-hydroxytryptamine (serotonin)
LD light–dark
MEL melatonin
4P-PDOT 4-phenylpropionamidotetraline
PT pars tuberalis
PTX pertussis toxin
SCN suprachiasmatic nuclei
SP short photoperiod neglected when the therapeutic potential of the hor-
mone is assessed,
19 especially because MEL has recent-
ly been demonstrated to bind to quinone reductase
(QR2), an enzyme with well-known oxidoreductive
properties.
20
Whether MEL has autocrine or paracrine effects is also
an important question.MEL might indeed act locally at
sites where or close to where it is produced.This is prob-
able, especially when extrapineal sources are consid-
ered.For example,in the retina,MEL is known to inhib-
it the release of dopamine.
21 The fact that enzymatic
deacetylation of MEL occurs in the retina or brain of a
variety of vertebrates,
22 along with the detection of low
amount of N-acetyltransferase mRNA in tissues other
than the pineal and retina,
9 also favors the concept of a
local role for MEL. One could thus imagine an evolu-
tionary sequence that starts with MEL being a local
modulator within the cell or in neighboring cells (eg,
light and dark adaptation in the retina, or food adapta-
tion in the gut).The second step would involve the use
of MEL as a hormone to control a variety of responses.
Even though the local role of MEL may be common or
universal, most of our knowledge concerns the role of
MEL as a hormonal transducer of photic/photoperiod-
ic information,and it is this aspect we will deal with.
As usual for many other hormones, MEL acts princi-
pally through specific protein receptors (see below).
However the hormone’s high lipophilicity enables it to
penetrate all organs within the body,all structures with-
in the brain, as well as all compartments within cells.
Interactions with specific intracellular proteins like
calmodulin or tubulin
23 have been reported and,even if
our knowledge is still poor,this could also be part of the
mechanisms involved.
Melatonin receptors
The first experiments on brain MEL receptors were car-
ried out in the late 1970s.
24-26 The low reproducibility of
the radioligand quality has prevented further develop-
ment. It was the introduction of 2-[
125I]iodomelatonin
([
125I]MEL), first used as a ligand for MEL radioim-
munoassay,
27 which opened the recent development of
the MEL receptor field.This potent MEL receptor ago-
nist, the first pharmacological tool available, led to the
detection of high–specific activity binding sites, first on
membrane fractions of whole rat brain
28 and then by
auradiotography on rat brain sections.
29
Initially, [
125I]MEL binding sites were classified on the
basis of pharmacological and kinetic differences into
two subtypes, ML-1 (now MT1,M T 2, and Mel1c) and
ML-2.* The ML-1 binding site has high-affinity MEL
receptors (Kd<200 pM) with a consensus rank order of
drug potency in inhibiting [
125I]MEL binding as follows:
2-iodomelatonin > 6-chloromelatonin ≥ MEL > 6-
hydroxymelatonin > N-acetylserotonin >> 5-hydroxy-
tryptamine.The ML-2 binding sites are characterized by
a Kd in the nanomolar range with a distinct pharmaco-
logical profile,notably a similar affinity for MEL and N-
acetylserotonin.
33,34 Due to difficulties in their charac-
terization and to their low affinity,which does not seem
to be compatible with the circulating MEL levels, less
attention had been given to these ML-2 binding sites.
The recent identification of MT3 receptor reopens this
question (see below).
Molecular identification of MEL receptor subtypes
The cloning of the first high-affinity MEL receptor was
a landmark in MEL receptor research history.This was
achieved by using an expression cloning strategy to iso-
late the complementary DNA encoding for MEL recep-
tor of Xenopus laevis dermal melanophores.
35This Xeno-
pus MEL receptor cDNA encoded a protein with seven
putative transmembrane regions that led to its classifi-
cation within the superfamily of G-protein–coupled
receptors.
35 Identification of the Xenopus receptor
sequence using homology-based screening methods led
to the subsequent identification of three types of verte-
brate MEL receptors.Two receptor subtypes with high-
affinity for MEL (initially termed Mel1a and Mel1b, but
now called MT1 and MT2) have been cloned and char-
acterized from sheep pars tuberalis (PT), human SCN
and hamster and rat hypothalamus.
36,37 In sheep PT,alle-
lic isoforms of MT1 receptors (termed Mel1a(α) and
Mel1a(β), respectively) have been identified.
38 A third
subtype of high-affinity MEL receptor was cloned from
a chicken brain library and termed the Mel1c.
39The first
Xenopus receptor to be isolated was a Mel1c receptor,
which exists in two allelic isoforms,Mel1c(α) and Mel1c(β).
So far,no mammalian homologue of the Mel1c receptor
has been isolated, but cDNA fragments for a nonmam-
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* These classifications come from the Nomenclature Committee of the
IUPHAR.
30-32 IUPHAR nomenclature does not include receptors found in non-
mammalian species, which explains the terminology Mel1c. The older termi-
nology ML-1/ML-2 should not be confused with the new one. MT1, MT2, and
Mel1c correspond to ML-1; the old ML-2 is now called MT3. malian Mel1b have. All this molecular work has also
demonstrated that the characteristics of the high-affini-
ty receptors are present in each of the three related
receptors (MT1,MT 2,and Mel1c).
Very probably this is only the beginning of a long list.A
receptor structurally related to the MEL receptors has
already been isolated
40,41 with a very interesting distrib-
ution of expression in neuroendocrine tissues.
42The nat-
ural ligand for this receptor has not been identified
(could it be a MEL metabolite?).More recently,a MEL
receptor with a nanomolar affinity,called MT3,has also
been isolated.The MT3 site is not a G-protein–coupled
receptor, but corresponds to a binding on the enzyme
quinone reductase.
20 Moreover, considering the
lipophilic nature of hormone, the probability of a
nuclear site of action of MEL is very high, and such a
site will be identified one day soon.
Localization of melatonin receptors
Since 1987, the use of [
125I]MEL as a ligand with a high
specific activity has permitted studies on the localization
of MEL receptors (or more exactly binding sites) of the
MEL-1 family (MT1,MT 2,and Mel1c).The binding sites
appear to be widespread in vertebrates. Comparative
distribution studies reveal the presence of MEL binding
sites in the brain of five vertebrate classes (fish,amphib-
ian, reptiles, birds, and mammals).The most relevant
feature is that the distribution of MEL binding sites in
lower vertebrates is much larger than in mammals, and
they are consistently found in areas associated with
retinorecipient and integrative structures of the visual
system.
43 In mammals the situation is more contrasted.
Contrary to what is generally claimed, in mammals,
MEL receptors are also present in a large number of
structures.They have been described in more than 110
brain structures,among them the internal granular layer
and the external plexiform layer of the olfactory bulb,
lateral septum, septohippocampal nucleus, caudate
putamen bed nucleus of the stria terminalis, SCN,
mediobasal hypothalamic nuclei,paraventricular nuclei
of the hypothalamus,paraventricular nuclei of the thal-
amus, intergeniculate leaflet, central and medial amyg-
daloid nucleus,inferior colliculus,fasciculus retroflexus,
substantia nigra,and frontal,orbitofrontal,and parietal
cortex.
44-46 However,a great variability has been noted in
the number and location of labeled structures among
the species,as well as large differences in receptor den-
sity between structures and in the same structures
between species. Few structures are common, even
among species from the same family,
44 and very proba-
bly this should be correlated either to the numerous
photoperiodic responses, which are different from one
species to another, or to the many different effects
described for MEL (see below).
Among all these structures, the pituitary PT, which
shows the highest density of MEL receptors and is the
only structure found consistently labeled in all mammals
so far studied,and the SCN,which contains MEL recep-
tors in many species, are considered as two major sites
for MEL action (see below).However,it should also be
pointed out that MEL receptors/binding sites have been
identified in numerous peripheral organs.The role of
these receptors has not yet been extensively studied,but
their presence explains the reported direct action of
MEL,for example,on blood vessels
47-49 and on cell-medi-
ated and humoral immune function
50 on Leydig and
luteal cells.
51 Its also indicates that the MEL message
can be read at different levels of the organism, which
should be taken into account when the potential thera-
peutic properties of MEL or MEL analogues are con-
sidered, especially as specific binding sites have been
reported in several neoplastic tissues.
52,53
The availability of new molecular tools following the
cloning of different subtypes of MEL receptor has per-
mitted a more precise analysis of their distribution.
Using in situ hybridization, it was shown that the MT1
receptor mRNA is, in rodents, present within the SCN,
paraventricular thalamus, and PT.
54 The MT2 subtype
seems to be mainly expressed in the retina (also in hip-
pocampus),
31,32,37,55 where its expression is linked with the
well-known MEL-induced inhibition of dopamine
release. Its expression in the SCN is not yet clarified.
MT2-specific oligonucleotides were reported to gener-
ate a signal in mice SCN by nonradioactive in situ
hybridization,
32 but using a 0.6-kb long riboprobe,Poirel
et al
56 were unable to detect any signal by in situ
hybridization within the rat SCN. Moreover, 4-phenyl-
propionamidotetraline (4P-PDOT) and 4-phenyl-
acetamidotetraline (4P-ADOT), two molecules that
specifically displace 2-iodomelatonin binding from MT2
binding sites expressed in transfected cells, do not dis-
place 2-iodomelatonin binding in the SCN.
55 As target-
ed molecular disruption of the MT1 receptor in mice
resulted in the total disappearance of 2-iodomelatonin
binding in brain tissues including the SCN,it seems that
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60the well-described SCN 2-iodomelatonin binding sites
are translated from MT1 mRNA.
However, although it is difficult to detect MT2 receptors
in the SCN, either by their pharmacological binding pro-
files or by their mRNA expression,the two known antag-
onists of this receptor subtype (4-PDOT and 4P-ADOT)
appear to have a functional effect on the SCN circadian
clock and inhibit in vitro the MEL-induced phase advance
of SCN activity.
32These apparently discrepant data suggest
the involvement of a third receptor subtype expressed in
the SCN and binding MEL and 4P-PDOT/4P-ADOT
with high affinity, but 2-iodomelatonin with low affinity.
As the phase-shifting response in MT1-deficient mice is
blocked by pertussis toxin (PTX),
55 this receptor subtype
would be also a G-protein–coupled receptor.
Signal transduction
The major bioassays that have been used to determine
signal transduction are as follows: the condensation of
pigment granules in the melanophores of amphibians
57;
the inhibition of calcium-dependent electrical
field–stimulated 
3H-dopamine release from rabbit reti-
na
34; the second messenger changes in ovine PT
58,59; the
hormonal secretion in neonatal pars distalis of rats
60;the
acute inhibition and phase shift of neuronal firing in
rat/mouse SCN slices in vitro;and the vascular vasocon-
striction in rat tail artery.
In amphibian dermal melanophores, MEL affects
melanin movement through a PTX-sensitive G-pro-
tein,
61 and the pineal hormone decreases cyclic adeno-
sine monophosphate (cAMP) accumulation.
62The same
signaling pathway is used in PT.
59 MEL indeed has no
effect on the basal level of cAMP in the PT of hamster
and sheep, but inhibits forskolin-induced cAMP accu-
mulation,
59,63,64 as well as forskolin-induced phosphoryla-
tion of the transcriptional activator cAMP-responsive
element binding protein (CREB).
64,65This effect of MEL
is PTX sensitive,indicating coupling of the receptor to a
Gi-protein.
63,64 However, a cholera toxin–sensitive com-
ponent also mediates the inhibition of forskolin-stimu-
lated cAMP accumulation,
58 implying coupling through
a Go-protein. Interestingly, pretreatment with MEL
results in a sensitization of adenylate cyclase, and a
potentiated cAMP response to forskolin stimulation.
66,67
In the neonatal rat anterior pituitary, MEL has effects
on numerous signal transduction pathways (inhibition
of cAMP and accumulation of cyclic guanosine
monophosphate [cGMP], suppression of diacylglycerol
synthesis and arachidonic acid release,decrease in intra-
cellular Ca
2+ concentration, and increase in membrane
potential).
60,68 MEL has also been reported to influence
the phospholipase C and the diacylglycerol-mediated
activation of the protein kinase C.
31,69
The cloning of MEL receptor cDNA has permitted the
development of cell lines in which either MT1 or MT2
recombinant receptors are expressed.It is thus possible
to link specific MEL receptor subtypes with specific sig-
nal transduction responses. Functionally, when the
cloned receptor subtypes (hMT1 and hMT2) are
expressed in the different cell lines tested (COS-7,NIH-
3T3, CHO, human HEK293, human HeLa, and murine
Ltk cells),they inhibit forskolin-stimulated cAMP accu-
mulation,confirming the coupling of MEL receptors to
this transduction pathway,as previously observed in tis-
sues.Moreover,studies with heterologous expression of
mammalian MEL receptors have helped characterize
additional signal transduction pathways. In short, acti-
vation of recombinant human MT1 receptors elicits mul-
tiple cellular responses that are mediated by both PTX-
sensitive and PTX-insensitive G-proteins. Not only is
the inhibition of forskolin-induced cAMP accumulation
observed,
70-72 but a potentiation of the prostaglandin
F2α–induced release of arachidonate and hydrolysis of
phosphoinositide is noted.
70 The functional significance
of this differential G-protein coupling was further deci-
phered: Gi2- and Gi3-proteins mediate adenylyl cyclase
inhibition through a PTX-sensitive mechanism, while
the PTX-insensitive Gq/11-protein is coupled to phos-
pholipase Cβ activity. Furthermore, activation of the
MT1 receptor induces a transient elevation of cytosolic
calcium ion concentration and an accumulation of inos-
itol phosphate.
71,72
The recombinant MT2 receptor is also coupled to inhi-
bition of adenylyl cyclase activity by a PTX-sensitive G-
protein.
37 Additionally, activation of the recombinant
MT2 receptor specifically inhibits cGMP levels via the
soluble guanylyl cyclase pathway.
73
What does this multiplicity of MEL effects mean for
MEL receptors in vivo? Heterologous overexpression
reveals the potential to couple to a specific signal trans-
duction pathway only. For in vivo work, this should be
interpreted in the context of pathways identified in each
specific tissue. For more details, we refer to recent
review articles by Masana and Dubocovich
74 and von
Gall et al.
75
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The different cloned MEL receptor subtypes that are
required to perform specific functions possess intrinsic
differences.This is evident in terms of both the cell tissue
distribution and the signal transduction pathways
involved.Over the next few years,the identification of the
links between specific target sites for MEL,specific MEL
receptor subtypes, and particular physiological actions
will be a great challenge.For this,many more pharmaco-
logical investigations are required.There is especially a
great need for selective agonists and antagonists.
Many such pharmacological studies have been done
31,32,45,57
and are still performed in native tissue models,especially
ovine PT cells and amphibian melanophores.Advances
in the molecular biology of MEL receptor subtypes,how-
ever, have permitted the development of gene cloning
and expression technologies.Different cell lines (COS-7,
NIH-3T3, and CHO) expressing high levels of specific
recombinant receptors (either hMT1 or hMT2) provide
the means for a rapid characterization of receptor-medi-
ated ligand binding and functional responses.
Numerous agonists and antagonists have been devel-
oped and are already available (Tables I and II)
34,57,46,76-92
and the further development in the engineered cell sys-
tems will quickly increase this number. In addition to
their usefulness as pharmacological tools for studying
the physiological role of MEL receptor subtypes, they
have started to be tested for clinical applications most-
ly for circadian-based disorders. However, presently, in
all recombinant systems used,no MEL receptor agonist
with a rate of selectivity over 100 for MEL receptors
subtypes in intact tissues is currently available.
80 How-
ever,some partial agonists or antagonists have selectiv-
ity above 100 and could be considered as selective MT2
analogues,and thus be used to distinguish the MT2 from
MT1 receptors in mammalian tissue.
Role of melatonin
Melatonin and seasonal functions
Environmental lighting acting through the eyes in mam-
mals has a profound effect on the rhythm of MEL syn-
thesis.The duration of the peak of MEL secretion is pos-
itively correlated with the length of the night. It is
through these changes in duration of MEL synthesis that
the brain is able to integrate photoperiodic information.
This explains the present use of this hormone in farming
to control seasonal functions (eg, fur growth, reproduc-
tion, and milk production).This also opens therapeutic
prospects if we consider the hypothesis of Wehr
93 “that
the photoperiod-induced changes in the duration of
MEL secretion drive the annual cycle that occur in sea-
sonal affective disorders.”The exact mechanism of action
of MEL is unclear.The duration of nocturnal MEL pro-
duction is the key signal,
5 but the existence within this
signal of a MEL-driven circadian rhythm of sensitivity to
MEL has been proposed to explain the photoperiodic
response.
94 The MEL receptors involved are most prob-
ably of the MT1 subtype. Indeed, the gene of the only
other MEL receptor subtype found in mammals,MT2,is
nonfunctional in two highly photoperiodic species,Siber-
ian and Syrian hamsters.The target sites mediating the
MEL control of the photoperiod-dependent seasonal
functions and especially the annual sexual cycle have not
yet been totally determined.One structure,however,the
pituitary PT,which contains a very high density of MEL
receptors in all mammals studied is thought to be of pri-
mary importance. Its density in MEL receptors exhibits
clear seasonal changes in seasonal species, but not in
nonphotoperiodic mammals,
95,96 and its implication in the
control of seasonal secretion of prolactin has been
demonstrated.
97-99The PT has already been used to delin-
eate the MEL’s signal transduction pathways (see above)
and thus appears to be a good model to study how the
cellular response can distinguish between long- and
short-duration MEL signals.The cAMP-mediated path-
ways appear to be central to the MEL readout.Pretreat-
ment with MEL has been demonstrated to induce a sen-
sitization of adenylate cyclase, and a potentiated cAMP
response to forskolin stimulation.
66,67 MEL pretreatment
to potentiate cAMP accumulation in the PT is duration
dependent (between 0-16 h) and corresponds well with
the duration of the nocturnal MEL signal.
66
Most probably, the integration of the photoperiodic
message throughout the change in the duration of the
MEL signal in a given structure will depend on altered
levels of expression of specific genes in that structure.
The most likely route by which this could be achieved is
through MEL’s effect on transcription factors. Several
cAMP-responsive genes, including the transcriptional
inhibitor inducible cAMP early repressor (ICER) and
the clock gene Per1 are rhythmically expressed in the
PT.The nocturnal MEL signal is crucial for the rhythmic
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expression of these genes.
100-103 Per1 mRNA levels in the
PT rise shortly after the dark-to-light transition,
103-105
immediately after the decline of the nocturnally elevat-
ed MEL signal. Per1 mRNA accumulation is followed
6h   later by an elevation in nuclear Per1 protein lev-
els.
106,107 Removal of the pineal gland abolishes rhythmic
PT gene expression,and extension of the dark phase of
the lighting cycle dampens the amplitude of Per1 and
Agonists Receptor(s) Reference
AH-001 (2-acetamido-8-methoxytetralin) MT1/MT2 76
AH-017 (2-chloroacetamido-8-methoxytetralin) MT1/MT2 76
AMMTC (N-acetyl-4-aminomethyl-6-methoxy-9-methyl-1,2,3,4-tetrahydrocarbazole) MT1/MT2/Mel1c*7 7
MT1/MT2
† 78
2-Bromomelatonin MT1/MT2 79
2-Chloromelatonin MT1/MT2/ Mel1c 80
6-Chloro-2-methylmelatonin MT1/MT2 80
6-Hydroxymelatonin MT1/MT2
‡ 81
MT1/MT2
† 78
GG-012 (4-methoxy-2-(methylene propylamide)indan) Partial MT1/MT2 76
GR 128107 (3-(1-acetyl-3-methylpiperidine)-5-methoxyindole)  Partial MT1/MT2
§ 82
GR 196429b (1-[2-(N-acetyl)aminoethyl]-7,8-dihydrofuro[2,3-γ]-2,3-dihydroindole·HCl) MT1/MT2 76, 83
MT1/MT2
  84
HEAT (5-hydroxyethoxy-N-acetyltryptamine) MT1 85
IIK7 MT2
§ 86
2-Iodomelatonin MT1/MT2/Mel1c 87
8M-ADOT (8-methoxy-2-acetamidotetralin) MT1/MT2 80
8M-PDOT (8-methoxy-2-propionamidotetralin) MT1/MT2 80
5-MCA-NAT (5-methoxycarbonylamino-N-acetyltryptamine) MT3 80
6-Methoxymelatonin MT1/MT2
‡ 80
5-Methoxyluzindole MT3 80
Partial MT2
‡ 80
ML23 (N-(3,5-dinitrophenyl)-5-methoxytryptamine) MT1/MT2 34,57
N-Acetylserotonin MT2 80
Partial MT1/MT2
‡ 80
4P-PDOT (4-phenyl-2-propionamidotetraline) Partial MT2
‡ 81
Partial MT2
¶ 88
S 20098 (N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide) MT1/MT2/ Mel1c 46,83,89
MT1
# 90
Partial MT2
# 90
S 20642 Partial MT1
#,** 90
Partial MT2
# 90
S 22029 MT1
# 90
Partial MT2
# 90
S 22365 MT1
# 90
Partial MT2
# 90
S 22480 Partial MT1
# 90
Partial MT2
# 90
Table I. Melatonin receptor agonists. Specific and currenty used molecules are presented in bold. Agonist are considered as specific when the
MT1/MT2 or MT2/MT1 ratio obtained in recombinant melatonin receptors is >100. *On dopamine release in retina; 
†on tail artery; 
‡in COS-7 cells
expressing recombinant hMT1 or hMT2; 
§in NIH-3T3 cells expressing recombinant hMT1 or hMT2;  in CHO cells expressing recombinant hMT1 or
hMT2; 
¶inhibition of leuckocyte rolling in the microcirculation; #in HEK293 expressing recombinant hMT1 or hMT2; **in ovine pars tuberalis tissues.ICER expression in PT cells.
102,103,106 What is the biologi-
cal significance of Per1 and ICER expression in the PT?
The unique sensitivity of Per1/ICER expression to MEL
in the PT suggests that these genes may be intrinsic to
the MEL readout mechanism.
107,108The complete under-
standing of the MEL/photoperiodic readout requires a
link with the identified downstream response in the PT.
This is still difficult.The PT has indeed been demon-
strated to relay photoperiodic/MEL information to lac-
totroph cells in the pituitary through production of a
prolactin-releasing (or release inhibitor) factor.This fac-
tor,termed “tuberlin,”
67,99 has not yet been identified.
Photoperiod-induced changes in prolactin secretion,how-
ever, are not enough to explain the annual sexual cycle.
This implies that to mediate photoperiodic information
MEL must act on other target sites.This multisite of action
concept is supported by the observation that a long-dura-
tion MEL infusion,which mimics short photoperiod (SP),
in hamsters with lesions of the dorsomedial hypothalamus
is unable to induce a decrease in luteinizing hormone lev-
els,while the prolactin levels decrease normally.
109,110 More-
over,in the sheep,MEL implants in the mediobasal hypo-
thalamus block the effects of SP on luteinizing hormone
but not on prolactin,while implants close to the PT inhib-
it prolactin secretion.
111 Interestingly, in hamsters, MEL
binding sites have been detected in the dorsomedial hypo-
thalamus (although at a very low density) and their den-
sity depends on the photoperiod (author’s laboratory,
unpublished data).
This hypothesis of a parallel and concomitant action of
MEL on different structures to transduce the photoperi-
odic message is very attractive.Via changes in duration of
MEL secretion,the photoperiod is known to control not
only the annual reproductive cycle,but also a large num-
ber of other seasonal functions (eg,hibernation,daily tor-
por, fur color changes, migration, etc). Considering that
not all these functions are expressed in all species and
that,even when a given function is expressed,the control
mechanisms involved are very different from one species
to another (eg,SP induces an activation of the sexual axis
in sheep but an inhibition in Syrian and Siberian ham-
sters;hibernation depends directly on photoperiod in the
Syrian hamster, while in the European hamster it
depends on a “circannual clock”[itself entrained by pho-
toperiod]), it is probable that MEL acts on different
structures depending on the species and the function.This
concept explains the large interspecies differences in the
distribution of MEL receptor–containing structures
observed in mammals. In regard to photoperiodic
responses,results obtained with the various MEL recep-
tor antagonists should be considered. The antagonist 
S 20928 has been shown to block the SP-induced body
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Antagonists Receptor(s) Reference
DH97 (N-pentanoyl-2-benzyltryptamine) MT2 86
GR 135533 Mel1c 86
GR 128107 (3-(1-acetyl-3-methylpiperidine)-5-methoxyindole)  MT2 80
HEAT (5-hydroxyethoxy-N-acetyltryptamine) MT2 85
KI85 MT2 86
Luzindole (2-benzyl-N-acetyl-tryptamine) MT1/MT2/Mel1c 80,86,90
MT2>MT1 80
4P-ADOT (4-phenyl-2-acetamidotetraline) MT2 80
4P-CADOT (4-phenyl-2-chloroacetamidotetraline) MT2 80
4P-PDOT (4-phenyl-2-propionamidotetraline) MT2 80
Mel1c
# 86
S 20928 (N-[2-(1-naphthyl)ethyl]cyclobutylcarboxamide) MT1/MT2 91
MT1
#,** 92
S 20642 (N-[2-(7-methoxy-1-naphthyl)ethyl]cyclobutylcarboxamide)
S 20929 Mel1c
# 86
S 22153 MT1/MT2 83,92
Table I. Melatonin receptor antagonists. Specific and currently used molecules are presented in bold. Antagonists are considered as specific when the
MT1/MT2 or MT2/MT1 ratio obtained in recombinant melatonin receptors is >100. #In HEK293 expressing recombinant hMT1 or hMT2; **in
ovine pars tuberalis tissues.mass increase and to increase basal metabolism in the
garden dormouse.
112 S 22153 is a MEL ligand character-
ized as a putative MEL antagonist of MT1 and MT2 MEL
receptor subtypes,
92 which blocks the phase-shifting effect
of MEL in mice,
83 the behavioral changes in mice induced
by short-day exposure,
113,114 and the potentiation induced
by MEL of electrically evoked contraction of isolated rat
tail arteries. S 22153 appears to be able to differentiate
different photoperiodic responses, at least in the Syrian
hamster: it decreased the total hibernation duration
observed in animals exposed to SP and low temperatures,
and significantly inhibited the increase in interscapular
brown adipose tissue mass.However,neither the gonadal
atrophy nor the body mass increase induced by SP was
affected by S 22153 (author’s laboratory, unpublished
data).To our knowledge,this is the first demonstration of
a pharmacological dissociation of photoperiodic-con-
trolled seasonal functions.Through changes in duration
of its nocturnal peak, MEL can also distribute the pho-
toperiodic message to all peripheral structures containing
MEL receptors,which explains the increase in immunity
observed under SP conditions in some species.
Melatonin and circadian functions
The diurnal organization of physiological processes
relies on endogenous circadian oscillator(s) that gener-
ate rhythms and are capable of being entrained to cyclic
environmental factors (eg, LD cycle). Such clocks con-
vey circadian information to the rest of the organism via
nervous and/or endocrine pathways. In most nonmam-
malian vertebrates,the rhythmic synthesis and secretion
of MEL is the direct output of such clocks and the
rhythmic changes in the concentration of circulating
MEL are fundamental to circadian rhythmicity.
115 In
mammals, it is generally assumed that the pineal gland
is not involved in the generation and maintenance of cir-
cadian rhythmicity. Pinealectomy indeed appears to
have little effect on the circadian rhythm of activity.
116
Therefore, it was concluded that, contrary to nonmam-
malian species, circulating rhythmic MEL had a very
limited role in circadian organization.The MEL rhythm,
however,is only one of the efferent signals of the clock.
It is probable that for the circadian organization of func-
tions, circadian information is distributed via a number
of different efferent clock signals. Pinealectomy has lit-
tle effect on circadian organization, perhaps because,
even without MEL,the circadian signal can be integrat-
ed through other clock outputs.
117,118 This will not pre-
clude an important role for MEL in circadian organiza-
tion. Subtle desynchrony of several physiological func-
tions after pinealectomy has been described
119 and the
reentrainment of rat locomotor activity rhythm is mod-
ified after a phase-shift of the LD cycle.
120 One week
after pinealectomy the firing rate rhythm of SCN neu-
rons in vitro is altered, as well as the daily rhythm of
responsiveness to MEL.
121 MEL is also known to inter-
fere with metabolic activity (glucose utilization and pro-
tein synthesis) of the SCN.
122 
In addition,because the synthesis of MEL is under SCN
control, the SCN may use the daily MEL signal to dis-
tribute the circadian message to any system that can
“read” it, ie, to any structure or organ possessing MEL
receptors, either in the central nervous system or in the
periphery.
6,123This concept explains many observations in
the literature: MEL (or the MEL agonist and selective 
5-HT2c antagonist S 20098) inhibition of spontaneous
and light-evoked activity of cells in the intergeniculate
leaflet)
91;MEL-enhancing splenic lymphocyte prolifera-
tion (attenuated by the antagonist luzindole)
50,124; MEL-
induced inhibition of leucocytes rolling and adhesion to
rat microcirculation
88;MEL-induced vasoconstriction of
cerebral and tail arteries
49; and the regulation of emo-
tional behavior by MEL.
113,114 What could be the mecha-
nism involved? Clock gene expression is widespread in
mammalian tissues,but does not exhibit cell-autonomous
self-sustaining rhythmicity, except in the SCN and the
retina. Rather, it appears that cyclical expression in the
periphery is driven by the SCN.The role of MEL in reg-
ulating rhythmic clock gene expression in peripheral tis-
sues as described in the PT (see above) may be one of
the mechanisms for tissue-specific regulation of the
phase of rhythmicity. Interestingly, in rat PT, it has been
demonstrated that the circadian rhythm of MEL recep-
tor density is suppressed after pinealectomy and MEL
drives this rhythm directly.
125,126
Most of the results described above concern the role of
endogenous MEL.As regards the potential therapeutic
use of MEL or MEL derivatives,the effect of exogenous
MEL must also be considered.
Chronobiotic properties of melatonin
A chronobiotic effect means that exogenous MEL can
influence, directly or indirectly, the phase and/or the
period of the circadian clock. In term of therapeutic
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65applications, this means that exogenous MEL (or a
MEL agonist and selective 5-HT2c antagonist such as 
S 20098) can be used as a pharmacological tool to
manipulate sleep–wake cycle and other circadian
rhythms.For a long time,it has been known that admin-
istration of MEL can entrain free-running activity
rhythms in rodents.
43,127 For example, Redman et al
128
demonstrated that daily subcutaneous injections of
MEL to rats strongly affect the locomotor activity
rhythm. MEL and some agonists entrain the free-run-
ning locomotor activity rhythm of animals and entrain-
ment only occurs when the MEL injection time coin-
cides with the onset of activity. If the injection is given
at any other time, the rhythm continues to free-run
until this coincidence occurs.However,all these exper-
iments
43,128 were based on bolus administration of MEL.
Behavioral arousal (1–4 h before activity onset
129,130) is
known to induce a phase advance of the locomotor
activity rhythm in Syrian hamster. Consequently, the
arousal associated with the injection-induced daily han-
dling of the rats may also interfere with the results. In
support of this idea is the fact that a small percentage
of the control animals became entrained to vehicle
administration in the early experiments.
128
In order to analyze the direct action of exogenous MEL
on circadian organization, we consider it necessary to
administer MEL in such a way that it does not by itself
induce entrainment and to eliminate the nonspecific
disturbance of the animals. MEL administration via
timed access to drinking water has been shown to be an
efficient way to entrain free-running activity rhythms in
the rat: the entrainment occurs at the same circadian
phase and with the same phase angle to MEL onset.
131
However, like the bolus administration experiments,
this technique does not allow precise control of the
duration of the peak MEL signal.The duration of MEL
is known to provide essential information, at least in
photoperiodic terms.To address these points,a chronic
infusion device has been developed, which allows the
animal freedom of movement in its cage and provides
continuous drug infusion (over several months) of con-
trolled duration and dose without handling.
132,133
Daily infusions of MEL for 1, 8, or 16 h, or twice 1 h
entrained the circadian rhythms of core body tempera-
ture,running-wheel activity,and general activity to 24 h.
Nevertheless, regardless of the dose, the efficiency of
MEL infusion decreased if it lasted a long time (16 h).
During entrainment,when the intrinsic period of the cir-
cadian pacemaker is equal to the period of the Zeitge-
ber (or synchronizer),it is assumed that the pacemaker
maintains a constant phase relation with the Zeitgeber.
With daily injection or oral administration of MEL,the
onset of activity is linked to the time of administration
and the phase angle is close to zero. When MEL is
administered by daily infusion, the phase angle differ-
ence between the entrained rhythm and the Zeitgeber
(MEL) depends upon the duration of the infusion peri-
od.A negative phase angle is observed and its value
increases with the duration of the infusion period. In
addition to the effects on phase angle,another response
has been observed.With an 8-h infusion and more evi-
dently with a 16-h infusion, MEL administration
induced a change in the free-running period in the first
days. The period was lengthened compared with the
saline infusion, suggesting that MEL delays the pace-
maker each day until entrainment occurs. In other
words, with a long duration of infusion, entrainment
occurs earlier than predicted by the model based on the
MEL injection experiments. Moreover, the magnitude
of the change in period increased significantly with the
duration of that infusion.These observations cannot be
explained on the basis of a sensitivity window,but rather
suggest that the chronobiotic properties of MEL imply
an active mechanism on the circadian clock.This con-
clusion is supported by the results obtained after a
“skeleton”infusion;two 1-h infusions with an interval of
15 h, corresponding to the extremities of the 16-h infu-
sion.Under these conditions,MEL induced entrainment
after a time during which circadian periods were either
lengthened in a fraction of the animals or shortened in
the others. However, all animals responded in such a
way that,once entrained,their active phase occurred in
the shorter time interval between the MEL signals.This
finding suggests that to achieve entrainment, MEL has
to induce either a phase delay (when the period was
shortened) or a phase advance (when the period was
lengthened). Such a dual effect of MEL has also been
reported in other studies. For example, when rats expe-
rience a 5-h phase advance of the dark onset in LD con-
ditions,those injected daily at the new dark onset reen-
trained with a decreased latency, some of the animals
did so by phase delays, whereas others did so by phase
advances.
134 Infusion of MEL has been reported to
entrain hamsters or Arvicanthis ansorgei, a diurnal
rodent, by inducing phase advances when the free-run-
ning period was longer than 24 h and phase delays when
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132,135All these observa-
tions strongly suggest that the effects of exogenous
MEL depend on the period before entrainment.
Does melatonin cause “true” entrainment?
Entrainment means that the period of the observed
rhythm must adjust to and equal the Zeitgeber cycle
(T),and a stable phase relationship must be established
between the rhythm and Zeitgeber cycle.
136According to
the nonparametric model of entrainment, this synchro-
nization process occurs through daily phase shifts, with
the size and direction of shifts defined in the
phase–response curve (PRC).
137 This has been demon-
strated by experiments using light as a synchronizer and
little is known about the synchronizer properties of
MEL and, for example, the limits of entrainment to
MEL are not yet well defined.In a recent study,Slotten
et al
138 have studied this problem by administering MEL
for a series of T values.The results indicate that the lim-
iting phase-advance value, to which the rat activity
rhythm entrains to MEL infusion, is approximately 35
min.Entrainment occurred at about circadian time (CT)
12;thus,at this phase of the activity cycle,MEL infusion
induced the phase advance necessary to entrain the
rhythm.The maximal daily phase-shift values defined by
the MEL PRC
139 and the magnitude of phase-shift
responses to a single MEL injection
140 ranges from 15 to
52 min.The entrainment limits found in this study cor-
respond quite well to these maximal phase-advance val-
ues.We can thus conclude that in the rat, daily acute
MEL administration causes “true” entrainment as
defined by Enright.
141 Until now,such experiments have
never been replicated with a MEL agonist.
Sites of action for the chronobiotic effects 
of melatonin
In all the experiments reported above, the responsive-
ness to MEL is restricted to a narrow window of sensi-
tivity,which is generally late in the subjective afternoon,
but depends upon the duration of the MEL signal as
well as the previous free-running period.The finding
that pinealectomized rats entrain to daily MEL admin-
istration
133,140 indicates that endogenous MEL is not nec-
essary for the entrainment effect of exogenous MEL,for
example,by entraining a window of sensitivity to MEL.
94
Nocturnal MEL production is a direct output of the
SCN circadian clock. Exogenous MEL is effective at a
time when endogenous MEL is not produced or present
in the general circulation. Consequently the effects of
MEL administration in vivo,as important as they are in
terms of potential clinical applications,appear not to be
related to the role of endogenous MEL on circadian
functioning.This conclusion is reinforced by the obser-
vation that to obtain entrainment of the circadian activ-
ity rhythm of rodents kept under constant darkness,high
doses of MEL have to be used, independently of the
mode of administration.
131,133,142These doses of MEL pro-
duce peak serum levels 100- to 1000-fold higher than the
endogenous MEL nighttime levels.The necessity of such
a high dose of MEL is unlikely to be a consequence of
its rapid metabolism. Appropriate photoperiodic
response is,indeed,obtained when MEL is administered
via a similar subcutaneous infusion system with a dose
that mimics the endogenous secretion profile.
94,143 Most
likely, this high dose of MEL is needed because it is an
integral part of the response observed.
Especially because in vitro administration of MEL can
phase shift the firing rate of SCN neurons in brain slices
(rat,mouse),
69,144 it is generally believed that MEL medi-
ates these effects through the high-affinity MEL recep-
tors located within the SCN.
29,107,125 This view is support-
ed by the high correlation between the density of MEL
receptors within the SCN and the ability of daily MEL
administration to entrain the free-running activity
rhythm in mammals. Contrary to the rat, mouse, and
Djungarian hamster, rodents that can be entrained by
daily MEL administrations and in which a high density
of MEL receptors is observed within the SCN,the mink
(Mustela vison) does not appear to have specific MEL
receptors (at least 2-iodomelatonin binding sites) with-
in the SCN. This animal does not entrain to MEL.
89
Newborn Syrian hamsters express MEL receptors in the
SCN, but shortly after birth the receptor number
decreases.
145,146 Young hamsters are entrainable by daily
acute MEL administration,while in the adult MEL can-
not entrain
129,147,148 or can only do so under particular
experimental conditions (eg, long-term infusions).
132,149
Since SCN-lesioned hamsters whose rhythmicity has
been restored with fetal hypothalamic graft are
entrained by daily MEL injection, and since MEL is
known to accelerate the reentrainment of circadian
rhythm in rat subjected to a shift in the LD cycle,
134 it is
clear that the chronobiotic effect of MEL is the conse-
quence of a direct action on the clock.This conclusion is
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antagonist (S 22153) in vivo blocks the phase-advancing
effect of MEL
83 and that after administration of various
MEL receptor agonists (AH-001,AH-017, and GG-012,
see Table I) an increase in the amplitude of the noctur-
nal MEL peak is observed.
76
Which receptor subtypes are involved? Siberian ham-
sters lacking a functional MT2 receptor show circadian
responses to MEL.
150 Similarly, the most robust entrain-
ing response to MEL,synchronization of developing cir-
cadian pacemakers in Syrian hamsters by MEL injec-
tions,
151 occurs in the absence of a functional MT2
receptor within the SCN. This strongly suggests the
implication of MT1 receptors or at least a partial redun-
dancy of function between MT1 and MT2.In the in vitro
experiments in animal models with both subtypes,where
effects are obtained with physiological doses of MEL,
the mechanisms involved appear to be complex. For
example, two distinct effects of MEL have been
described: an acute inhibitory effect on neuronal firing
and a phase-shifting effect in the rhythm in electrical
activity.
55 Until recently, it was assumed that the inhibi-
tion of electrical activity was part of the cellular mecha-
nism underlying the phase shifting effect of MEL.How-
ever, in mice with a targeted deletion of the MT1
receptor, the acute inhibitory effect of MEL was abol-
ished, while the phase-shifting effect remained intact.
55
This phase-shift disappears when the MT2 antagonist 4P-
PDOT is added.
32This suggests that either a low density
of MT2 receptors can still produce phase shift
75 or that an
as yet unidentified MEL receptor subtype is involved
(see above).In contrast to previous studies,van den Top
et al
152 have recently demonstrated the absence of a par-
ticular window of sensitivity for MEL to inhibit SCN
neuronal activity. Such inhibition is also obtained with
the MEL agonist and selective 5-HT2c antagonist 
S 20098
91 and is blocked with low doses of the MEL
antagonist S 20928.Such a lack of a window of sensitivi-
ty is in contrast to MEL’s phase-shifting effect,and indi-
cates that distinct cellular mechanisms are involved in
the acute inhibitory effect and in the phase-shifting
effect of MEL.This may be related to the two types of
effects observed in vivo after the daily 8- or 16-h MEL
infusions
133 described above.
Even though the presence of MT1 and/or MT2 receptors
appears to be a necessary condition for the chronobiotic
effect of MEL, if these high-affinity receptors were the
only mechanism involved, then it would be difficult to
explain why a high dose of MEL is needed to obtain such
an effect in vivo.This suggests that other neural mecha-
nisms are involved.At concentrations as high as those
needed to observe an effect on circadian activities in mam-
mals, MEL is known to inhibit 5-HT reuptake in nerve
endings.
153,154A possible interaction between MEL and the
5-HT system within the SCN should thus be considered.
The inhibition of 5-HT reuptake is not crucial for the
MEL effect on the circadian rhythms.
155 MEL might then
act at the level of the postsynaptic 5-HT receptors.This
idea is supported by the observation that administration
of 5-HT receptor agonists in vivo also phase shift the
rodent circadian clock and by the work of Dugovic et al,
156
who have shown that in vivo exogenous MEL counter-
acts the 5-HT2A agonist– or antagonist–induced effects
on sleep.Eison et al
157 also demonstrated a modulation of
5-HT2A receptor–mediated behavioral responses by
exogenous MEL (high dose) and Ying et al
91 found that
high dose of MEL exerted inhibitory effect on firing rate
in the intergeniculate leaflet by mimicking the effect of 5-
HT agonists.Such direct implication of the 5-HT system
in the chronobiotic effect of MEL, however, remains to
be experimentally demonstrated.
Conclusions and future prospects
Disturbed circadian rhythmicity due to life conditions
(shift work,jet lag) or to involuntary circumstances (ill-
ness, aging) has been associated with numerous mental
and physical disorders.This has important consequences
on human safety, performance, and productivity.The
importance of circadian (and seasonal) rhythmicity for
human health and welfare is becoming increasingly rec-
ognized and a need for treatment is now clear.
Problems may occur at various levels in the circadian
organization and drugs to reverse theses changes may
be directed toward the input pathways, the clock itself,
the output pathways,or ultimately the organ expressing
a particular rhythm.
Nocturnal secretion of MEL is an output signal of the
circadian clock that distributes the circadian message to
any structures/organs possessing MEL receptors,within
the brain or in the periphery.This explains why MEL
appears to act in so many different systems. Moreover,
due to the presence of MEL receptors within the SCN
itself, when MEL administered exogenously has clear
chronobiotic effects. Thus, through an action on the
clock,the hormone influences the temporal organization
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of a large number of functions (cardiovascular,digestive,
immune,etc).This also explains the wide range of report-
ed MEL effects.MEL is thus an attractive candidate for
manipulating circadian rhythms in humans.
The assessment of therapeutic potential of MEL calls
for a precise delineation of its sites and mechanisms of
actions.The recent (and future) development of specif-
ic agonists and antagonists for the human MEL recep-
tor subtypes opens new prospects.Without any doubt
these drugs are leading to therapeutic applications in
dissociating the different MEL actions at the different
levels of organization of the system. ❏
Melatonina
La melatonina (MEL) es una hormona que es sin-
tetizada y secretada por la glándula pineal, la cual
se ubica en la profundidad del cerebro, en res-
puesta a señales fotoperiódicas que se transmiten
desde la retina a través de un oscilador circadiano
que está en el núcleo supraquiasmático del hipo-
tálamo. El ritmo circadiano de la producción y libe-
ración de melatonina, que se caracteriza por una
actividad nocturna y un reposo diurno, constituye
una importante señal temporal para las estructu-
ras del cuerpo que pueden leerla. La melatonina
actúa a través de receptores de alta afinidad que
se ubican a nivel central y en numerosos órganos
periféricos. Se han clonado y caracterizado dife-
rentes subtipos de receptores: MT1 y MT2 (recep-
tores transmembranosos acoplados a proteína-G)
y MT3. Aun cuando su papel fisiológico no está
aclarado, las aplicaciones en el manejo del gana-
do por ahora incluyen el control de la reproduc-
ción estacional y la producción de leche. Como
potenciales aplicaciones terapéuticas la melatoni-
na exógena o un agonista de melatonina y ago-
nista selectivo del receptor 5-hidroxitryptamina 
(5-HT2c), como el S 20098, se pueden utilizar para
manipular los procesos circadianos como el ciclo
sueño vigilia, el cual frecuentemente se desorga-
niza en muchas condiciones, en especial en el tras-
torno afectivo estacional.
Mélatonine
La mélatonine (MEL) est une hormone synthétisée
et sécrétée par l’épiphyse, glande située profon-
dément dans le cerveau, en réponse à des signaux
photopériodiques transmis à partir de la rétine par
un oscillateur circadien endogène dans le noyau
suprachiasmatique de l’hypothalamus. Le rythme
circadien de la production et de la libération de
mélatonine, caractérisé par une activité nocturne
et une quiescence diurne, est un important signal
temporel pour les structures corporelles capables
de le lire. La mélatonine agit par l’intermédiaire
de récepteurs à haute affinité, tant centraux que
présents dans de nombreux organes périphé-
riques. Différents sous-types de récepteurs ont été
clonés et caractérisés : MT1 et MT2 (récepteurs
transmembranaires couplés à la protéine G) et
MT3. Cependant, leur rôle physiologique reste non
élucidé, bien que des applications de gestion du
cheptel soient déjà utilisées pour contrôler la
reproduction saisonnière et la production de lait.
Dans les applications thérapeutiques potentielles,
la mélatonine exogène ou par exemple, le 
S 20098, agoniste de la melatonine et antago-
niste sélectif du récepteur de la 5-hydroxytrypta-
mine (5-HT2c), peuvent être utilisés pour modifier
certains processus circadiens comme le cycle veille-
sommeil, qui sont souvent déréglés dans de nom-
breuses circonstances, tout particulièrement dans
les troubles affectifs saisonniers. 
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